April 2014

TreatmentTrends®: Psoriasis (EU) 2014


TreatmentTrends: Psoriasis (EU) will cover practice dynamics, current use and future use projections for key products, perceived product ad-vantages and disadvantages. While the report does cover all treatment categories (topicals, systemics, phototherapy and biologics), the empha-sis is on the biologic agents with added detail around the promotional en-vironment and awareness of products in development.
TreatmentTrends are a syndicated report series that provide longitudinal information on market dynamics. The reports provide insights into practice patterns, attitudes and perceptions and current and projected use of vari-ous products. They evaluate perceived product advantages and disad-vantages, as well as sales and messaging efforts of key market players. They are quantitative in nature with several open-ended questions for qualitative feedback.

Questions Answered in This Report:

  *   Determine the typical patient load and psoriasis severity in dermatolo-gists’ practices.

  *   Understand psoriasis treatment patterns, compare current patient shares of psoriasis treatments.

  *   Identify agents preferentially used as topical and systemic therapies in different European countries.

  *   Estimate recent trends in usage of topical agents, conventional sys-temic therapies and biologics.

  *   Determine the importance of clinical data for biosimilars in psoriasis on dermatologists’ intention to use biosimilars for this indication.

  *   Identify the attributes of biologics perceived as most valuable by der-matologists.


Sample Frame & Methodology:

~225 dermatologists complete a 45-minute online quantitative survey with several open-ended questions for qualitative feedback.

To qualify, respondents must meet the following criteria:

Minimum of 25 patients with psoriasis under management

Have been in practice a minimum of two years and a maximum of 30 years

More than 75 percent of professional time spent in clinical practice

Key Drugs Covered:

brodalumab, Enbrel, Humira, ixeki-zumab, MK-3222, Otezla (apremilast), Remicade, secuki-numab, Stelara, tofacitinib

Key Companies Mentioned:

AbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Janssen, Merck, Novartis, and Pfizer


- Final report in Powerpoint format

- Complete set of frequency tables, summary statistics, and cross tabulations can be provided upon request

- Proprietary question slide deck: Clients purchasing report prior to fielding will have the opportunity to include up to three proprietary questions

Related Reports:

- Pharmacor®: Psoriasis

- PatientBase®: Psoriasis in G7

- PatientBase®: Psoriasis in Brazil

- PatientBase®: Psoriasis in Russia

- PatientBase®: Psoriasis in India

- PatientBase®: Psoriasis in China

- PatientBase®: Psoriasis in Turkey

- PatientBase®: Psoriasis in Mexico

- PatientBase®: Psoriasis in South Korea

- Treatment Algorithms®: Psoriasis

- DecisionBase®: Psoriasis (Moderate to Severe)

- Physician and Payer Forum®: Psoriasis

Search Published Reports

Decision Resources Group brands include: